Cellective BioTherapy
Research Triangle Park, US · Founded 2015 · Delaware corporation
Cellective Biotherapy develops regulatory B10 cell-based immunotherapies designed to enhance or inhibit immune responses for treating cancers, autoimmunity, immunodeficiency, and infectious disease. Its pipeline focuses on first-in-class B cell-directed therapies.
BiotechHealthtech
Founders & leadership
Cellective BioTherapy was founded in 2015 by Thomas F. Tedder.
TF
Thomas F. TedderFounder
RB
Robert BonczekNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2015
▶$2.5MraisedMay 2015 · 2 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMay 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert BonczekExecutive Officer, Director, Promoter
- Thomas F. TedderExecutive Officer, Director, Promoter
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Cellective BioTherapy do?
- Cellective Biotherapy develops regulatory B10 cell-based immunotherapies designed to enhance or inhibit immune responses for treating cancers, autoimmunity, immunodeficiency, and infectious disease. Its pipeline focuses on first-in-class B cell-directed therapies.
- Who founded Cellective BioTherapy?
- Cellective BioTherapy was founded by Thomas F. Tedder in 2015.
- How much funding has Cellective BioTherapy raised?
- Cellective BioTherapy has disclosed $2.5M raised across 1 round.
- Where is Cellective BioTherapy headquartered?
- Cellective BioTherapy is headquartered in Research Triangle Park, US.